ImmunityBio Inc.’s recent filing unveils that its Director BLASZYK MICHAEL D acquired Company’s shares for reported $0.2 million on Jun 05. In the deal valued at $2.75 per share,71,915 shares were bought. As a result of this transaction, BLASZYK MICHAEL D now holds 71,915 shares worth roughly $ 0.12 million.
Then, Brennan John Owen bought 25,000 shares, generating $70,700 in total proceeds. Upon buying the shares at $2.83, the Director now owns 25,000 shares.
Before that, Clark Wesley bought 7,000 shares. ImmunityBio Inc. shares valued at $20,370 were divested by the Director at a price of $2.91 per share. As a result of the transaction, Clark Wesley now holds 8,000 shares, worth roughly $13360.0.
Piper Sandler downgraded its ImmunityBio Inc. [IBRX] rating to a Neutral from a an Overweight in a research note published on Monday, May 12, 2023; the price target was decreased to $4 from $10. PT values the company’s stock at a premium of 58.25 to its Monday closing price.
Price Performance Review of IBRX
On Monday, ImmunityBio Inc. [NASDAQ:IBRX] saw its stock fall -7.22% to $1.67. On the same session, the stock had its day’s lowest price of $1.62, but rose to a high of $1.85. Over the last five days, the stock has gained 8.44%. ImmunityBio Inc. shares have fallen nearly -67.06% since the year began. Nevertheless, the stocks have fallen -74.03% over the past one year. While a 52-week high of $7.10 was reached on 05/09/23, a 52-week low of $1.21 was recorded on 03/15/23. SMA at 50 days reached $2.0190, while 200 days put it at $3.0438. A total of 4.45 million shares were traded, compared to the trading of 3.39 million shares in the previous session.
Levels Of Support And Resistance For IBRX Stock
The 24-hour chart illustrates a support level at 1.5767, which if violated will result in even more drops to 1.4833. On the upside, there is a resistance level at 1.8067. A further resistance level may holdings at 1.9433. The Relative Strength Index (RSI) on the 14-day chart is 47.65, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.1521, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 31.03%. Stochastics %K at 82.29% indicates the stock is a selling.
How much short interest is there in ImmunityBio Inc.?
A steep rise in short interest was recorded in ImmunityBio Inc. stocks on Aug 30, 2023, growing by 2.82 million shares to a total of 26.72 million shares. Yahoo Finance data shows the prior-month short interest on Jul 30, 2023 was 23.9 million shares. There was a rise of 10.55%, which implies that there is a positive sentiment for the stock. In spite of short shares comprising just 20.66% of the overall stock float, the days-to-cover ratio (short ratio) rose to 11.28.
ImmunityBio Inc. [IBRX] – Who Are The Largest Shareholders?
In filings from The Vanguard Group, Inc., it is revealed that the company now owns 10,036,929 shares, or roughly 1.12% of the outstanding IBRX shares. In other words, the investor’s shares have risen by 1,982,098 from its previous 13-F filing of 8054831.0. Additionally, BlackRock Fund Advisors increased 41.90% of its stake after which the total value it holdings stand at $13,858,970, while SSgA Funds Management, Inc. added 4.81% of its stake to hold $4.47 million in the firm. Over the last quarter, Geode Capital Management LLC purchased 784,588 shares of ImmunityBio Inc., while Allen Holding, Inc. bought 0 shares. At present, JPMorgan Asset Management is holding 1,289,870 shares valued at $2.08 million. Northern Trust Investments, Inc. owned 1,094,477 shares of the company at the time of its most recent 13F filing, worth $1.76 million.
According to FactSet, ImmunityBio Inc.’s share price will average $5.00 in the next year, based on opinions of analysts polled by the firm. This is up nearly 177.78 percent from its previous closing price of $1.80. Analysts expect ImmunityBio Inc. stock to reach the higher price of $5.00, while the lowest price estimate is $5.00. However, 1 analyst have rated IBRX stock as a Buy in their predictions for 2023.